HT2 Evaluation of Tucatinib for HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis
Jun 1, 2021, 00:00
10.1016/j.jval.2021.04.046
https://www.valueinhealthjournal.com/article/S1098-3015(21)00263-1/fulltext
Title :
HT2 Evaluation of Tucatinib for HER2-Positive Breast Cancer Patients with Brain Metastases: A United States-Based Cost-Effectiveness Analysis
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(21)00263-1&doi=10.1016/j.jval.2021.04.046
First page :
Section Title :
Open access? :
No
Section Order :
11022